Huang TH - Search Results

1

Identification and characterization of ovarian cancer-initiating cells from primary human tumors.

Zhang S, Balch C, Chan MW, Lai HC, Matei D, Schilder JM, Yan PS, Huang TH, Nephew KP. Zhang S, et al. Among authors: huang th. Cancer Res. 2008 Jun 1;68(11):4311-20. doi: 10.1158/0008-5472.CAN-08-0364. Cancer Res. 2008. PMID: 18519691 Free PMC article.

2

Antimitogenic and chemosensitizing effects of the methylation inhibitor zebularine in ovarian cancer.

Balch C, Yan P, Craft T, Young S, Skalnik DG, Huang TH, Nephew KP. Balch C, et al. Among authors: huang th. Mol Cancer Ther. 2005 Oct;4(10):1505-14. doi: 10.1158/1535-7163.MCT-05-0216. Mol Cancer Ther. 2005. PMID: 16227399

3

Diverse gene expression and DNA methylation profiles correlate with differential adaptation of breast cancer cells to the antiestrogens tamoxifen and fulvestrant.

Fan M, Yan PS, Hartman-Frey C, Chen L, Paik H, Oyer SL, Salisbury JD, Cheng AS, Li L, Abbosh PH, Huang TH, Nephew KP. Fan M, et al. Among authors: huang th. Cancer Res. 2006 Dec 15;66(24):11954-66. doi: 10.1158/0008-5472.CAN-06-1666. Cancer Res. 2006. PMID: 17178894

4

Minireview: epigenetic changes in ovarian cancer.

Balch C, Fang F, Matei DE, Huang TH, Nephew KP. Balch C, et al. Among authors: huang th. Endocrinology. 2009 Sep;150(9):4003-11. doi: 10.1210/en.2009-0404. Epub 2009 Jul 2. Endocrinology. 2009. PMID: 19574400 Free PMC article. Review.

5

Epigenetics and ovarian cancer.

Nephew KP, Balch C, Zhang S, Huang TH. Nephew KP, et al. Among authors: huang th. Cancer Treat Res. 2009;149:131-46. doi: 10.1007/978-0-387-98094-2_6. Cancer Treat Res. 2009. PMID: 19763434 Review. No abstract available.

6

The epigenetics of ovarian cancer drug resistance and resensitization.

Balch C, Huang TH, Brown R, Nephew KP. Balch C, et al. Among authors: huang th. Am J Obstet Gynecol. 2004 Nov;191(5):1552-72. doi: 10.1016/j.ajog.2004.05.025. Am J Obstet Gynecol. 2004. PMID: 15547525 Review.

7

Loss of estrogen receptor signaling triggers epigenetic silencing of downstream targets in breast cancer.

Leu YW, Yan PS, Fan M, Jin VX, Liu JC, Curran EM, Welshons WV, Wei SH, Davuluri RV, Plass C, Nephew KP, Huang TH. Leu YW, et al. Among authors: huang th. Cancer Res. 2004 Nov 15;64(22):8184-92. doi: 10.1158/0008-5472.CAN-04-2045. Cancer Res. 2004. PMID: 15548683

8

Hypermethylation of 18S and 28S ribosomal DNAs predicts progression-free survival in patients with ovarian cancer.

Chan MW, Wei SH, Wen P, Wang Z, Matei DE, Liu JC, Liyanarachchi S, Brown R, Nephew KP, Yan PS, Huang TH. Chan MW, et al. Among authors: huang th. Clin Cancer Res. 2005 Oct 15;11(20):7376-83. doi: 10.1158/1078-0432.CCR-05-1100. Clin Cancer Res. 2005. PMID: 16243810

9

Dominant-negative histone H3 lysine 27 mutant derepresses silenced tumor suppressor genes and reverses the drug-resistant phenotype in cancer cells.

Abbosh PH, Montgomery JS, Starkey JA, Novotny M, Zuhowski EG, Egorin MJ, Moseman AP, Golas A, Brannon KM, Balch C, Huang TH, Nephew KP. Abbosh PH, et al. Among authors: huang th. Cancer Res. 2006 Jun 1;66(11):5582-91. doi: 10.1158/0008-5472.CAN-05-3575. Cancer Res. 2006. PMID: 16740693

10

Epigenetic "bivalently marked" process of cancer stem cell-driven tumorigenesis.

Balch C, Nephew KP, Huang TH, Bapat SA. Balch C, et al. Among authors: huang th. Bioessays. 2007 Sep;29(9):842-5. doi: 10.1002/bies.20619. Bioessays. 2007. PMID: 17688287

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,103 results

Search Page

Filters